

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract: (150 words)

 The persistence of measles in many regions demonstrates large immunity gaps, resulting from incomplete or ineffective immunization with measles-containing vaccines (MCVs). A key factor affecting MCV impact is age, with infants receiving dose 1 (MCV1) at older ages having a reduced risk of vaccine failure, but also an increased risk of contracting infection before vaccination. Here, we designed a new method—based on a transmission model incorporating realistic vaccination delays and age variations in MCV1 effectiveness—to capture this risk trade-off and estimate the optimal age for recommending MCV1. We predict a large heterogeneity in the optimal ages (range: 6–20 months), contrasting the homogeneity of observed recommendations worldwide. Furthermore, we show that the optimal age depends on the local epidemiology of measles, with a lower optimal age predicted in populations suffering higher transmission. Overall, our results suggest the scope for public health authorities to tailor the recommended schedule for better measles control.

31 **Main text:** (4992 words)

32 **Introduction:** (724 words)

33 Measles is a highly contagious childhood infection¹ caused by the measles virus. The virus is 34 primarily spread through respiratory droplets and aerosols², and symptoms include cough, f fever, malaise, and a characteristic maculopapular rash¹. Historically, measles was a major 36 childhood disease, infecting almost all individuals in early life³ and resulting in $2-3$ million 37 deaths per year¹. The introduction of measles vaccines in the 1960s significantly reduced the 38 global number of measles cases and deaths⁴, with estimated deaths in 2021 reduced to 39 approximately $128,000^5$.

40

41 However, despite the indisputable global success of the vaccine, measles remains endemic in 42 multiple countries. Many regional elimination targets for 2020 were not met⁶, reflecting the 43 difficulty of reaching the high immunization coverage needed for measles elimination⁴. These 44 difficulties were compounded during the COVID-19 pandemic, which caused interruptions in 45 routine vaccinations and supplementary immunization activities $(SIAS)^{6,7}$, resulting in new 46 measles outbreaks in 18 countries⁶. Since 2020, 140 countries have reported at least 1 case per 47 year to the World Health Organization (WHO), and over 30 countries have reported over 1,000 48 cases in a year⁸.

49

 Although the immunity gaps that drive continued measles transmission are mainly caused by insufficient vaccine coverage, they also result from vaccine failures. One avertable cause of these vaccine failures is the vaccination age: vaccination with the first dose of measles-53 containing vaccine (MCV1) at younger ages results in a higher risk of vaccine failure⁹. Two main mechanisms have been proposed to explain this result: blunting by maternal antibodies 55 and immaturity of the infant immune system $10,11$. However, despite the potential consequences

 on measles control – e.g., changing the recommended MCV1 age as a potential control intervention – the impact of vaccination age on vaccine effectiveness (VE) has only recently 58 been quantified⁹.

 As illustrated in Figure 1a, the increasing effectiveness of MCV1 with age should result in a trade-off in risks when recommending MCV1 age: reducing the age of vaccination increases the risk of vaccine failure, while increasing the age worsens the risk of infection before vaccination. Hence, by balancing these risks, the recommended MCV1 age may be optimized to minimize measles incidence. Furthermore, location-specific factors, such as transmission level, are expected to affect this trade-off by changing the mean age of infection (MAI), 66 resulting in different optimal ages^{12,13}. Following this conceptual model, one expects the optimal vaccination age to depend on the local epidemiology of measles.

 As seen in Figure 2, however, the global homogeneity in recommended MCV1 ages contrasts 70 with the observed heterogeneity in measles incidence¹⁴. The partial Spearman rank correlation coefficient between MCV1 ages and countries' mean annual incidence was only –0.12 (p- value: 0.53) in countries with ≥1 measles case per 1 million per year, when controlling for Human Development Index (HDI), an aggregate measure of countries' longevity, education, 74 and standard of living¹⁵. Of the 205 MCV1 recommendations obtained, 70% of recommendations were at 9 months (69 countries) or 12 months (109 countries), reflecting the recommendations from the WHO: MCV1 at 9 months in countries with ongoing transmission 77 and at 12 months in countries with low transmission¹⁴. Although these recommendations generally reflect the trade-off in risks, they may not capture the complexity of factors that impact measles epidemiology, such as further transmission variation driven by differences in social contact patterns or vaccination coverage.

 The relative homogeneity in MCV1 recommendations suggests opportunities for refining the MCV1 age to leverage this risk trade-off. Here, we propose a new method—based on a mechanistic model of endemic measles transmission incorporating realistic, data-driven models of MCV1 delay and VE variation with age—to estimate the optimal age to recommend MCV1. As a proof of concept, we used this method to estimate the optimal MCV1 age in a range of synthetic test populations. In these populations, we varied parameter values across realistic ranges to identify factors determining optimal age (Figure 1b). We show that a mismatch between the optimal and recommended ages can potentially increase measles incidence. Furthermore, we show that the optimal age is sensitive to location-specific determinants of measles epidemiology, with transmission level having the greatest effect, followed by the social contact structure and vaccination coverage. Overall, our study suggests that the optimal MCV1 age is highly population-specific and, hence, more heterogeneous than the current recommendations reflect. Our findings thus suggest the potential to adjust MCV1 ages to reduce measles incidence, taking steps toward eventual elimination.

Methods: (1,453 words)

Data on measles incidence, recommended MCV1 age, and the Human Development Index

99 We gathered data on MCV1 recommended age from the WHO¹⁶ and the European Centre for 100 Disease Prevention and Control $(ECDC)^{17}$, supplemented with reports from individual 101 countries in cases of missing data^{18–23}. We also collected country-level estimates of annual 102 measles incidence for 2010–2019 from the WHO¹² and HDI values for the same period from 103 the United Nations Development Program¹⁵.

105 The relationship between MCV age and vaccine effectiveness

 To quantify how vaccination age affects MCV VE, we fitted a statistical model to reported 107 estimates of MCV VE, obtained from a systematic review⁹. For MCV1 VE, to reduce uncertainty in MCV1 age, we only included estimates with an MCV1 age interval of <3 months. For the included MCV1 VE estimates, we calculated each estimate's standard error 110 from reported 95% confidence intervals.

112 We then fitted a shape-constrained additive model $(SCAM)^{25}$ to the logit-transformed MCV1 VE estimates. Specifically, we used a monotonically increasing P-spline basis with 4 knots, weighted according to precision, with standard errors transformed using the Delta method. We then calculated approximate simultaneous confidence intervals to assess uncertainty in model fit^{26} . To include this uncertainty in the transmission model, we considered 5 curves corresponding to the predicted 2.5%, 25%, 75%, and 97.5% quantiles and the maximum 118 likelihood estimate (MLE) from the SCAM.

 For MCV dose 2 (MCV2) VE, too few estimates were available to assess age dependencies (Supplementary Figure 1). We, therefore, assumed MCV2 VE to be constant and equal to the mean MCV2 VE.

The distribution of MCV1 delay

 To incorporate realistic distributions of MCV delay (*i.e.*, the delay between the recommended age and the actual age of administration), we obtained data on MCV1 delay in 45 low and 127 middle-income countries $(LMICs)^{27}$, where most measles deaths occur⁵. The data consisted of the observed 25%, 50%, and 75% quantiles of the delay distribution. We excluded any countries with negative median delay. We initially fitted an Exponential distribution, which 130 failed to capture the observed long right tails. Hence, we then fitted a Lomax distribution²⁸ (an

 extension of the Exponential distribution with longer right tails to capture long delays) to every country by minimizing the squared distance between the simulated and observed quantiles. To summarize the variation in delay distributions, we clustered the Lomax distribution parameters 134 using Partitioning Around Medoids (PAM) Euclidean distance clustering²⁹. The number of 135 clusters was determined using the average silhouette method³⁰ and the Gap statistic³¹, with 500 bootstraps.

Model of measles transmission and vaccination

 To simulate measles incidence when recommending MCV1 at different ages, we constructed a mechanistic model of measles transmission and vaccination, incorporating the aforementioned data-driven statistical models of MCV1 delay and age-specific MCV1 VE. The model was a deterministic SIR model, which split the population by infection status into susceptible, infectious, recovered, and protected by maternal antibodies. For sufficiently large populations, 144 deterministic models have been shown to capture the dynamics of measles $32,33$.

 The model was age-structured, to allow the vaccination age to vary. The model split the population into monthly age groups between ages 0 to 59 months, then into 5-year age groups between ages 5 to 79. We assumed a uniform age distribution and constant population size. Contacts between age groups were parameterized using data-derived social contact matrices 150 (SCM)^{34,35}. To capture the variability in social contact structure, we selected 7 SCMs derived from China, India, Japan, Moscow, South Africa, the UK, and the USA, representing the clusters identified in a previous study that clustered SCMs from 35 countries and 277 153 subnational administrative regions³⁴.

 To model vaccination with two doses of MCV, we added a vaccinated susceptible state to model infants with primary vaccine failure (*i.e.*, infants who received the vaccine but failed to 157 mount an effective immune response³⁶). Vaccination was assumed to occur when aging from one age group to the next. For the first dose (MCV1), at a given age, individuals were either vaccinated or not vaccinated, determined by the recommended MCV1 age, delay distribution, and MCV1 coverage. If unvaccinated, individuals entered the next age group's susceptible compartment. If vaccinated, the probability of successful vaccination was determined by the VE-age relationship. If successful, infants were protected and entered the recovered compartment of the next age group. If unsuccessful, they remained unprotected and entered the next age group's vaccinated-susceptible compartment. The process remained the same for MCV2, but vaccination occurred when aging from the vaccinated susceptible compartment. The recommended MCV2 age was modeled as 6 months after the recommended MCV1 age, 167 aligning with the modal gap between reported MCV schedules $16-23$.

 Full model details, including parameterization, are included in the supplementary materials (Supplementary Table 1).

Recapitulating reported pre-vaccine mean ages of measles infection

 To calibrate transmission parameters, we compared the simulated MAI with historical reports 174 from the pre-vaccine era³⁷, which ranged from 24 months to 72 months (Supplementary Table 2). We grouped the MAI into three transmission levels: 48–72 months (low-transmission level), 36–48 months (medium-transmission level), and 24–36 months (high-transmission level). 177 Based on the evidence of age heterogeneities in transmissibility^{38,39}, we incorporated a 178 parameter (q) representing the transmissibility of <5-year-olds relative to \geq 5-year-olds. Finally, 179 for a range of fixed R_0 values in the interval 10–20, we calibrated q by fitting the predicted

 pre-vaccine MAI to 3 MAI target values (lower bound, mid-value, and upper bound) in each 181 transmission level. For each target MAI, $5 R_0$ —q pairs were selected, resulting in a total of 15 pairs for each transmission level.

 The model was run assuming a constant population of 10 million for 500 years, at which point 185 convergence to the equilibrium solution was determined by the magnitude of the derivatives⁴⁰. If this convergence criterion was not fulfilled, the final 20 years of the simulation were extracted, and a linear model fit to the modeled cases. The simulation was judged to have 188 converged if the slope of the linear model was less than 10^{-3} per day, corresponding to a change of <1 case per year. If convergence was achieved, the modeled MAI was calculated and compared against the target MAI using the sum of squares.

The optimal age to recommend MCV1

 We simulated recommending MCV1 at different ages, monthly from 6 to 20 months. For each recommended age, we calculated the corresponding annual incidence at equilibrium, then identified the MCV1 age that minimized the incidence aggregated over all age groups. Furthermore, to identify factors that have the greatest impact on the optimal age we varied these factors across realistic values (Figure 1b).

 We simulated measles annual incidence using the model described above, simulating without vaccination for 50 years, then introducing vaccination and running the model for a further 950 years. Vaccination was modeled as beginning from the recommended MCV1 age, with delays in MCV1 and MCV2 following the delay distributions described above. The vaccine coverage was defined as the proportion of a birth cohort vaccinated by 24 months after the recommended 204 MCV dose age. Based on reported MCV coverages from the WHO 14 , we set MCV1 coverage

205 at 45%, 55%, 65%, 75%, and 85%, and MCV2 coverage at 5% points lower than the set MCV1 206 coverage.

207

 To assess variation in optimal ages, we estimated the optimal age for every combination of SCM (China, India, Japan, Moscow, South Africa, UK, USA), vaccine coverage (MCV1 coverages: 45%, 55%, 65%, 75%, 85%), delay distribution (short delay and long delay), VE curve (2.5%, 25%, 75%, 97.5% quantiles, and the MLE), and transmission level (low-, 212 medium-, and high-transmission, with 15 R_0 -q pairs for each level), see Figure 1b. Any combination that failed to converge to the equilibrium solution according to the abovementioned convergence criteria, at any recommended MCV1 age, was removed. Optimal ages were then calculated and compared. To facilitate this comparison and evaluate the current 216 WHO clustering of recommendations, we clustered (using PAM clustering²⁹ based on 217 Euclidean distance, and the silhouette method³⁰ to determine cluster sizes) the estimated optimal ages to identify groups of SCM.

219

220 Numerical Implementation

221 Analysis was carried out using R version $4.1.1^{41}$, using the R package "tidyverse"⁴². Partial 222 correlations were calculated using the package "ppcor"⁴³. SCAMs were fitted using the 223 package "scam"⁴⁴. Lomax distributions were fitted using the R package "optim"⁴⁵, using the 224 algorithm "L-BFGS-B"⁴⁶. PAM clustering was carried out using the R packages "cluster"⁴⁷ 225 and "factoextra"⁴⁸. The measles model was implemented in C and R, using the R package 226 "pomp"⁴⁹. Parameter fitting was carried out using the subplex algorithm⁵⁰, in the R package 227 "hloptr^{"51}. Mixed-effect models were fitted using the package "lme4"⁵². Figures were created 228 using the R packages "ggplot2"⁵³, "viridis"⁵⁴, "wesanderson"⁵⁵, "patchwork"⁵⁶, and "ggh4x"⁵⁷.

Results: (1242 words)

MCV1 effectiveness increases with age of receipt

 After applying our inclusion criteria, we analyzed a total of 52 VE estimates from 16 studies. As shown in Figure 3a, the point estimates and the confidence intervals of VE varied greatly. Lower ages displayed particularly high variation in VE estimates. A large part of the overall variation was captured by the SCAM (59.3% of deviance explained), which estimated an 237 increase in VE with age, confirming the results of the earlier meta-analysis⁹. The SCAM estimated the VE at 64.5% at 6 months, approaching 100% by 20 months. Hence, the model confirms that, for infants ≤20 months, the effectiveness of MCV1 increases with age of receipt.

Empirical data on the reported age of vaccination reveal MCV1 is frequently delayed

 Based on data from 43 countries that met our inclusion criteria, we found that delays in receiving MCV1 were prevalent (median (range) of median delay: 0.6 (0.1, 1.3) months), exceeding 3 months for 25% of infants in 9 countries (median (range) of 75% delay quantile: 1.8 (0.4, 5.6) months).

 In 41 of the 43 countries, we successfully fitted the Lomax distribution (see Supplementary Figure 2), which recapitulated the 50% and 75% quantiles of the observed delay distributions. Using PAM clustering, we identified two broad groups of countries (Figure 2b, Supplementary Figure 2): one group with longer right tails (long delay, 35 countries, medoid country: Uganda, survey median (IQR): 0.6 (0, 2.2) months, model median (IQR): 0.6 (0.2, 2.2) months) and another group with shorter right tails (short delay, 5 countries, medoid country: Turkey, survey median (IQR): 0.7 (0.2, 1.6) months, model median (IQR): 0.7 (0.2, 1.6) months). For both clusters and all observed countries, the estimated parameters resulted in median delays in the

 range 0.1 to 1.3 months, corresponding to a median delay of up to 14% when MCV1 was recommended at 9 months. Taken together, this analysis indicates MCV1 is frequently delayed, with important implications for measles control by vaccination, modeling the transmission dynamics of measles, and estimating the optimal age of MCV1.

 By combining the delay distribution with age-specific MCV1 effectiveness, we calculated the cumulative effective vaccine coverage, defined as the proportion of a birth cohort protected by the vaccine by a given age (Figure 2c). This effective coverage reflected the conceptual trade- off in risks outlined in Figure 1a: increasing the recommended MCV1 age left a birth cohort susceptible to infection for longer but also increased MCV1 effectiveness and, hence, the long- term proportion of the cohort protected. Furthermore, the delay distribution also determined the effective coverage, with longer delays resulting in lower proportions of a birth cohort protected 18 months after the recommended age (Figure 2d).

 Heterogeneity in transmissibility is necessary to recapitulate pre-vaccine reports of measles MAI

 When comparing model-derived MAIs to historical estimates in the pre-vaccine era, we found 272 that, for typically reported values of R_0 ⁵⁸ between 12 and 18, the model failed to recapitulate the MAIs for multiple SCMs (Supplementary Figure 5). However, once age-specific transmissibility was included, the transmission model could recapitulate all historical estimates of MAIs for all SCMs, except the Chinese SCM for a MAI of 24 months. All fitted values of 276 q and R_0 converged according to the convergence criteria. These fitted pairs displayed a 277 negative association, such that increases in R_0 were compensated by decreases in q. Hence, this calibration allowed us to define parameter regions that reproduce each transmission level (Figure 4) for inclusion in the transmission model.

The optimal age to recommend MVC1 is sensitive to transmission level, contact structure, and vaccine coverage

 Of all the parameter sets modeled, 99.4% fulfilled our convergence criteria. Across those, we identified a unique optimal age ranging between scenarios from 6 to 20 months. Furthermore, the predicted optimal ages varied greatly between scenarios (see Figure 5a-b). For example, the optimal age for the low-transmission level with the China SCM at 85% MCV1 coverage ranged from 15 to 20 months, whereas the high-transmission level at 45% vaccine coverage with the South Africa SCM ranged from 6 to 7 months. Moreover, recommending a non- optimal MCV1 age on incidence could result in up to a 2.6-fold increase in incidence, although the impact of an age mismatch was similarly scenario-dependent (see Figure 5a, Table 1).

 Of the factors we varied, the transmission level impacted the optimal age the most. At 45% MCV1 coverage, parameterized with the USA SCM, the optimal age ranged between 11 to 13 months in a low-transmission setting and 7 to 9 months in a high-transmission setting. More generally, increasing transmission from low to medium decreased the optimal age by an average of 1.6 months, and increasing from low to high transmission resulted in an average decrease of 3.6 months (Supplementary Table 3). Higher transmission resulted in lower MAIs and increased the risk of infection at younger ages, thus resulting in younger optimal ages to compensate for this risk. Accordingly**,** increases in the pre-vaccine MAIs resulted in increases in the optimal age (Supplementary Figure 6a). After controlling for the MAI, the additional 301 impact of R_0 and q on the optimal age was minimal (data not shown).

 Social contact structure also affected the optimal age to recommend MCV1. Even after controlling for transmission level and vaccine coverage, the range of optimal ages varied

 between SCMs: for example, from 6 to 7 months for the South Africa SCM to 9 to 12 months for the China SCM for a scenario with high transmission at 45% coverage. Depending on the MCV coverage–transmission level scenario considered, the optimal ages clustered into 2–5 308 groups. However, \geq 3 groups were typically required to capture the heterogeneity in optimal ages between SCMs (13/15 scenarios, Supplementary Figure 7). In most scenarios, the China SCM and the South Africa SCM tended to cluster independently, representing the SCMs with the oldest and youngest optimal ages respectively, with other SCMs clustering together, with optimal ages between these groups.

 Finally, vaccine coverage also impacted the optimal age. Specifically, increased coverage reduced measles incidence, resulting in higher optimal ages. For example, optimal MCV1 ages in a low-transmission setting with the South Africa SCM ranged from 7 to 11 months at 45% vaccine coverage and from 11 to 15 months at 85% vaccine coverage. In general, when accounting for transmission level and SCM, a 10-percentage point increase in MCV1 coverage resulted in an average increase in optimal age of 0.8 months (Supplementary Table 4). Overall, these results demonstrate the importance of location-specific factors of measles epidemiology for vaccine policy.

 The impact of variations in age-specific MCV1 effectiveness and delay distribution on the optimal age is minor

 Uncertainty in the vaccine effectiveness curve only marginally affected the optimal age. When holding all other parameters constant, varying the curve resulted in changes in the optimal age in only 12.0% of parameter sets. In cases where the optimal age varied, the effect was inconsistent, but generally, as the quantile of the VE curve increased, the optimal age decreased (Supplementary Figure 6b).

 Uncertainty in the MCV delay distribution had a similarly minor impact on optimal age. When holding all other parameters fixed, changing the delay distribution resulted in a change in optimal age in only 14.6% of parameter sets. When changes occurred, a higher optimal age was predicted for the short delay distribution (Supplementary Figure 6c).

Discussion: (1057 words)

 In this study, we developed a new method, based on a mechanistic model of measles transmission and vaccination, to estimate the optimal age to recommend MCV1. In particular, this model captured several complexities of measles epidemiology, including age-specific contacts, vaccination delays, and VE variations with age of receipt. For every scenario tested, we could identify a unique optimal age in the range of 6–20 months, contrasting the two ages recommended by the WHO. Moreover, we found that the optimal age was governed by location-specific factors, namely transmission level, vaccine coverage, and social contact structure. Overall, our results suggest that, in addition to increasing vaccine coverage, adjusting the recommended vaccination age could help minimize immunity gaps and reduce measles incidence, taking steps toward eventual elimination from endemic settings.

 A key result from our study is that the optimal age to recommend MCV1 may depend on the local epidemiology of measles. Specifically, we predict that populations suffering from higher measles transmission require a lower vaccination age. More generally, the impact of certain factors of local epidemiology can be understood by considering their effect on the MAI and transmission after vaccine introduction. This explains the effect of pre-vaccination 353 transmission levels (controlled by the parameters R_0 and q), which are correlated with post-vaccination transmission levels. Similarly, increasing vaccination coverage is dynamically

355 equivalent to reducing transmission⁵⁹, hence resulting in higher optimal ages. However, even at fixed transmission levels, the impact of social contact structure was strong. This result shows that, in addition to broad metrics quantifying the transmission of measles, detailed knowledge of social contact structure, quantified by data-derived SCMs, is needed to identify the optimal in a given population.

 In our simulations, two transmission parameters were required to recapitulate the range of transmission intensities (quantified by the MAI) observed in the pre-vaccine era. Unlike earlier 363 modeling studies^{60,61}, varying only the basic reproduction number was insufficient to reach target MAIs for all contact matrices. This discrepancy may be explained by the high age resolution and the inclusion of realistic SCMs in our model. More generally, this result suggests age heterogeneities beyond social contacts are necessary for the design of realistic models of measles. Here, we allowed the relative transmissibility of <5 year olds to vary, and calibrated values varied across multiple orders of magnitude (range: 0.005–46.3). This heterogeneity could also be interpreted as a correction to the SCM, as the SCMs used were derived for more modern populations than the pre-vaccine MAI estimates.

 As the main goal of our study was to establish a proof of concept, we chose the minimization endpoint of equilibrium incidence to estimate the optimal age in endemic settings. In real-world applications, however, this endpoint should be defined over shorter time scales, reflecting the time frame of control, and should be reassessed frequently as the optimal ages change with decreasing transmission. Additionally, other endpoints like hospitalization or deaths may be considered but will require extending our model to represent additional mechanisms of vaccine 378 protection, such as reduced disease severity in vaccine-breakthrough cases⁶². Importantly, considering other endpoints may change the nature of the trade-off in risks, in particular

380 because of the increased incentive to vaccinate early if mortality is increased in younger ages⁶³. Similarly, other endpoints, like the risk of invasion, will be needed to estimate the optimal age in elimination settings, where vulnerability to outbreaks may persist due to residual pockets of 383 susceptible individuals⁶⁴. Applying our model in such settings will require a stochastic formulation, due to the low number of cases and frequent extinctions that deterministic models cannot capture well.

 Furthermore, the real-world application of our method will require additional components beyond population-specific information on the SCM, vaccine coverage, and delay distribution, to fully characterize measles epidemiological dynamics in a target population. These include demography, as changes in population structure are expected to affect age-specific 391 transmission dynamics⁶⁵, with more circulation expected in younger populations⁶⁶. A second key component is seasonality in transmission, which can result from term-time increases in contacts among school-aged children⁶⁷ or the effect of climate on virus transmissibility⁶⁸. Therefore, a prerequisite to applying our method is a detailed model—identified, for example, 395 by fitting to long-term incidence data using modern statistical inference techniques —for capturing the local drivers of measles transmission.

 Another key consideration when applying our proposed method is SIAs. These additional immunization campaigns aim to rapidly increase population immunity by vaccinating target 400 demographics—typically children aged \leq 14 years—regardless of vaccination history⁶⁹. In general, such campaigns are expected to reduce transmission and, thus, increase the optimal age for MCV1. Hence, in settings where SIAs are routinely administered, MCV1 age should be optimized to maximize the effect of both interventions.

 Beyond the components listed above, our method could be extended to consider the effects of MCVs on other pathogens. Indeed, measles infection can cause immune amnesia, whereby the suppression of immune cells partially erases immune memory to previously encountered 408 pathogens⁷⁰. As a result, MCVs have beneficial indirect effects on other infectious diseases⁷¹. In addition, it has been proposed that MCVs directly affect non-measles pathogens, perhaps 410 because of enhanced trained immunity⁷². Beyond MCVs, our proposed method could also be applied to estimate the optimal age for vaccines against other childhood infections. We expect 412 the relationship between vaccination age and VE to be qualitatively similar for other vaccines, 413 even though the empirical evidence has remained more limited than for measles^{73,74}. As the measles vaccine is often combined with the mumps and rubella vaccines (MMR), the natural next candidates would be these two vaccines. Because mumps and rubella infection have 416 different transmissibility than measles (Mumps R_0 : 4–7⁷⁵, Rubella R_0 : 6–7⁷⁵), the risk trade- off underlying the optimal age is expected to differ. Hence, a future research question is how to extend our approach to identify the optimal age for combined vaccines.

 Despite the availability of effective vaccines for over 60 years, measles remains a considerable threat in many countries. Here, we propose that, alongside ever-necessary efforts to increase vaccine coverage, another effective intervention to reduce measles cases may be to tailor the vaccination age. Hence, our results suggest the scope for public health authorities to improve measles control and reach for eventual elimination by customizing the recommended vaccination schedule. More generally, as the trade-off underlying the optimal age is not specific to measles, our results could have ramifications for controlling many other vaccine-preventable diseases.

References:

- 1. Paules, C. I., Marston, H. D. & Fauci, A. S. Measles in 2019 Going Backward. *N. Engl.*
- *J. Med.* **380**, 2185–2187 (2019).
- 2. Wang, R., Jing, W., Liu, M. & Liu, J. Trends of the Global, Regional, and National
- Incidence of Measles, Vaccine Coverage, and Risk Factors in 204 Countries From 1990 to
- 2019. *Front. Med.* **8**, (2022).
- 3. Langmuir, A. D. Medical Importance of Measles. *Am. J. Dis. Child.* **103**, 224–226 (1962).
- 4. Dixon, M. G. *et al.* Progress Toward Regional Measles Elimination Worldwide, 2000–
- 2020. *Morb. Mortal. Wkly. Rep.* **70**, 1563–1569 (2021).
- 5. World Health Organization. Measles fact sheet. *World Health Organization*
- https://www.who.int/news-room/fact-sheets/detail/measles (2023).
- 6. World Health Organization. Measles and rubella strategic framework 2021-2030. *Measles*
- *and rubella strategic framework: 2021-2030* https://www.who.int/publications-detail-
- redirect/measles-and-rubella-strategic-framework-2021-2030 (2020).
- 7. Causey, K. *et al.* Estimating global and regional disruptions to routine childhood vaccine
- coverage during the COVID-19 pandemic in 2020: a modelling study. *The Lancet* **398**,

522–534 (2021).

- 8. World Health Organization. Measles Reported cases by country. *Global Health*
- *Observatory data repository* https://apps.who.int/gho/data/view.main.1540_62?lang=en (2021).
- 9. Hughes, S. L. *et al.* The effect of time since measles vaccination and age at first dose on measles vaccine effectiveness – A systematic review. *Vaccine* **38**, 460–469 (2020).
- 10. Gans, H. *et al.* Measles and mumps vaccination as a model to investigate the
- developing immune system: passive and active immunity during the first year of life.
- *Vaccine* **21**, 3398–3405 (2003).

- 11. Simon, A. K., Hollander, G. A. & McMichael, A. Evolution of the immune system in
- humans from infancy to old age. *Proc. R. Soc. B Biol. Sci.* **282**, 20143085 (2015).
- 12. McLean, A. R. & Anderson, R. M. Measles in developing countries Part I.
- Epidemiological parameters and patterns. *Epidemiol. Infect.* **100**, 111–133 (1988).
- 13. Mclean, A. R. & Anderson, R. M. Measles in developing countries. Part II. The
- predicted impact of mass vaccination. *Epidemiol. Infect.* **100**, 419–442 (1988).
- 14. World Health Organisation. WHO Immunization Data portal.
- https://immunizationdata.who.int/compare.html?COMPARISON=type1__WIISE/MT_AD
- _COV_LONG+type2__WIISE/MT_AD_INC_RATE_LONG+option1__MCV_coverage+
- 463 option2 MEASLES incidence&GROUP=Countries&YEAR=.
- 15. United Nations Development Program. *Human Development Reports: Data*
- *downloads*. *Human Development Reports* https://hdr.undp.org/data-center/documentation-and-downloads.
- 16. World Health Organisation. Vaccination schedule for Measles. *World Health*
- *Organisation* https://immunizationdata.who.int/pages/schedule-by-
- 469 disease/measles.html?ISO 3 CODE=&TARGETPOP GENERAL= (2021).
- 17. European Centre for Disease Prevention and Control. Measles: Recommended
- vaccinations. *Vaccine Scheduler* https://vaccine-
- schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=8&SelectedCountryIdB yDisease=-1 (2023).
- 18. Rochmyaningsih, D. Indonesian 'vaccine fatwa' sends measles immunization rates
- plummeting. *Science News* https://www.science.org/content/article/indonesian-vaccine-
- fatwa-sends-measles-immunization-rates-plummeting (2018).
- 19. Ministerio de Salud y Deportes de Bolivia. Esquema Nacional de Vacunación 2018.
- *Ministerio de Salud y Deportes* https://www.minsalud.gob.bo/es/42-pai/3067-esquema-de-

- vacunacion (2018).
- 20. Centers for Disease Control and Prevention. About Measles Vaccination | CDC.
- *Vaccines and Preventable Diseases* https://www.cdc.gov/vaccines/vpd/measles/index.html
- (2022).
- 21. Public Health Agency of Canada. Recommended immunization schedules: Canadian
- Immunization Guide. https://www.canada.ca/en/public-
- health/services/publications/healthy-living/canadian-immunization-guide-part-1-key-
- immunization-information/page-13-recommended-immunization-schedules.html (2007).
- 22. UNICEF. Know your child's immunization schedule | UNICEF India. *UNICEF India*
- https://www.unicef.org/india/know-your-childs-immunization-schedule.
- 23. KDCA. KDCA. *KDCA* https://www.kdca.go.kr.
- 24. Chapter 6: Choosing effect measures and computing estimates of effect. in *Cochrane*
- *Handbook for Systematic Reviews of Interventions version 6.4* (eds. Julian PT Higgins,
- Tianjing Li, & Jonathan J Deeks) (Cochrane, 2023).
- 25. Pya, N. & Wood, S. N. Shape constrained additive models. *Stat. Comput.* **25**, 543–559 (2015).
- 26. Ruppert, D., Wand, M. P. & Carroll, R. J. *Semiparametric Regression*. (Cambridge University Press, 2003).
- 27. Clark, A. & Sanderson, C. Timing of children's vaccinations in 45 low-income and middle-income countries: an analysis of survey data. *The Lancet* **373**, 1543–1549 (2009).
- 28. Lomax, K. S. Business Failures: Another Example of the Analysis of Failure Data. *J. Am. Stat. Assoc.* **49**, 847–852 (1954).
- 29. Leonard Kaufman & Peter J. Rousseeuw. Partitioning Around Medoids (Program
- PAM). in *Finding Groups in Data* 68–125 (John Wiley & Sons, Ltd, 1990).
- doi:10.1002/9780470316801.ch2.

- 30. Kaufman, L. & Rousseeuw, P. J. *Finding Groups in Data*. (John Wiley & Sons, Inc., 2005).
- 31. Tibshirani, R., Walther, G. & Hastie, T. Estimating the number of clusters in a data
- set via the gap statistic. *J. R. Stat. Soc. Ser. B Stat. Methodol.* **63**, 411–423 (2001).
- 32. Bjørnstad, O. N., Finkenstädt, B. F. & Grenfell, B. T. Dynamics of Measles
- Epidemics: Estimating Scaling of Transmission Rates Using a Time Series Sir Model.
- *Ecol. Monogr.* **72**, 169–184 (2002).
- 33. Grenfell, B. T., Bjørnstad, O. N. & Finkenstädt, B. F. Dynamics of Measles
- Epidemics: Scaling Noise, Determinism, and Predictability with the Tsir Model. *Ecol.*
- *Monogr.* **72**, 185–202 (2002).
- 34. Mistry, D. *et al.* Inferring high-resolution human mixing patterns for disease
- modeling. *Nat. Commun.* **12**, 323 (2021).
- 35. Mossong, J. *et al.* Social Contacts and Mixing Patterns Relevant to the Spread of
- Infectious Diseases. *PLOS Med.* **5**, e74 (2008).
- 36. Verguet, S. *et al.* Controlling measles using supplemental immunization activities: A
- mathematical model to inform optimal policy. *Vaccine* **33**, 1291–1296 (2015).
- 37. Anderson, R. & May, R. Vaccination against rubella and measles: Quantitative
- investigations of different policies. *J. Hyg. (Lond.)* **90**, 259–325 (1983).
- 38. Galanti, M. *et al.* Rates of asymptomatic respiratory virus infection across age groups. *Epidemiol. Infect.* **147**, e176 (2019).
- 39. Davies, N. G. *et al.* Age-dependent effects in the transmission and control of COVID-19 epidemics. *Nat. Med.* **26**, 1205–1211 (2020).
- 40. Soetaert, K., Petzoldt, T. & Setzer, R. W. Solving Differential Equations in R:
- Package deSolve. *J. Stat. Softw.* **33**, 1–25 (2010).
- 41. R Core Team. R: A Language and Environment for Statistical Computing. (2022).

- 42. Wickham, H. *et al.* Welcome to the Tidyverse. *J. Open Source Softw.* **4**, 1686 (2019).
- 43. Kim, S. ppcor: Partial and Semi-Partial (Part) Correlation. (2015).
- 44. Pya, N. scam: Shape Constrained Additive Models. (2022).
- 45. Nocedal, J. & Wright, S. J. *Numerical Optimization*. (Springer, 2006).
- 46. Byrd, R. H., Lu, P., Nocedal, J. & Zhu, C. A Limited Memory Algorithm for Bound
- Constrained Optimization. *SIAM J. Sci. Comput.* **16**, 1190–1208 (1995).
- 47. Maechler, M., Rousseeuw, P., Struyf, A., Hubert, M. & Hornik, K. cluster: Cluster
- Analysis Basics and Extensions. https://cran.r-
- project.org/web/packages/cluster/citation.html (2022).
- 48. Kassambara, A. & Mundt, F. factoextra: Extract and Visualize the Results of
- Multivariate Data Analyses. (2020).
- 49. King, A. A., Nguyen, D. & Ionides, E. L. Statistical Inference for Partially Observed
- Markov Processes via the R Package pomp. *J. Stat. Softw.* **69**, 1–43 (2016).
- 50. Rowan, T. Functional stability analysis of numerical algorithms. in (1990).
- 51. NLopt NLopt Documentation. https://nlopt.readthedocs.io/en/latest/.
- 52. Bates, D. *et al.* lme4: Linear Mixed-Effects Models using 'Eigen' and S4. (2022).
- 53. Wickham, H. *ggplot2: Elegant Graphics for Data Analysis*. (Springer-Verlang, 2016).
- 54. Garnier, S. *et al.* sjmgarnier/viridis: viridis 0.6.0 (pre-CRAN release). (2021)
- doi:10.5281/zenodo.4679424.
- 55. Ram, K., Wickham, H., Richards, C. & Baggett, A. wesanderson: A Wes Anderson
- Palette Generator. (2018).
- 56. Pedersen, T. L. patchwork: The Composer of Plots. (2022).
- 57. Brand, T. van den. ggh4x: Hacks for 'ggplot2'. (2023).
- 58. Guerra, F. M. *et al.* The basic reproduction number (R0) of measles: a systematic
- review. *Lancet Infect. Dis.* **17**, e420–e428 (2017).

- 59. Earn, D. J. D., Rohani, P., Bolker, B. M. & Grenfell, B. T. A Simple Model for
- Complex Dynamical Transitions in Epidemics. *Science* **287**, 667–670 (2000).
- 60. Magpantay, F. M. G., King, A. A. & Rohani, P. Age-structure and transient dynamics
- in epidemiological systems. *J. R. Soc. Interface* **16**, 20190151 (2019).
- 61. Farrington, C. P., Kanaan, M. N. & Gay, N. J. Estimation of the Basic Reproduction
- Number for Infectious Diseases from Age-Stratified Serological Survey Data. *J. R. Stat.*
- *Soc. Ser. C Appl. Stat.* **50**, 251–292 (2001).
- 62. Fappani, C. *et al.* Breakthrough Infections: A Challenge towards Measles
- Elimination? *Microorganisms* **10**, 1567 (2022).
- 63. Sbarra, A. N. *et al.* Estimating national-level measles case–fatality ratios in low-
- income and middle-income countries: an updated systematic review and modelling study.
- *Lancet Glob. Health* **11**, e516–e524 (2023).
- 64. Kohnen, M. *et al.* Diagnostic challenges and pockets of susceptibility identified
- during a measles outbreak, Luxembourg, 2019. *Eurosurveillance* **26**, 2000012 (2021).
- 65. Graham, M. *et al.* Measles and the canonical path to elimination. *Science* **364**, 584– 587 (2019).
- 66. Geard, N. *et al.* The effects of demographic change on disease transmission and
- vaccine impact in a household structured population. *Epidemics* **13**, 56–64 (2015).
- 67. Keeling, M. J. & Rohani, P. *Modeling Infectious Diseases in Humans and Animals*.
- *Modeling Infectious Diseases in Humans and Animals* (Princeton University Press, 2011).
- doi:10.1515/9781400841035.
- 68. de Jong, J. G. The survival of measles virus in air, in relation to the epidemiology of measles. *Arch. Für Gesamte Virusforsch.* **16**, 97–102 (1965).
- 69. World Health Organization. Planning and implementing high-quality supplementary
- immunization activities for injectable vaccines using an example of measles and rubella

vaccines: field guide. https://www.who.int/publications-detail-redirect/9789241511254

(2016).

- 70. Mina, M. J. *et al.* Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens. *Science* **366**, 599–606 (2019).
- 71. Mina, M. J., Metcalf, C. J. E., de Swart, R. L., Osterhaus, A. D. M. E. & Grenfell, B.
- T. Long-term measles-induced immunomodulation increases overall childhood infectious
- disease mortality. *Science* **348**, 694–699 (2015).
- 72. Aaby, P. *et al.* The optimal age of measles immunisation in low-income countries: a
- secondary analysis of the assumptions underlying the current policy. *BMJ Open* **2**,
- e000761 (2012).
- 73. Galil, K., Fair, E., Mountcastle, N., Britz, P. & Seward, J. Younger Age at
- Vaccination May Increase Risk of Varicella Vaccine Failure. *J. Infect. Dis.* **186**, 102–105 (2002).
- 74. Redd, S. C. *et al.* Comparison of Vaccination with Measles-Mumps-Rubella Vaccine
- at 9, 12, and 15 Months of Age. *J. Infect. Dis.* **189**, S116–S122 (2004).
- 75. Emilia Vynnycky & Richard G White. An introduction to infectious disease
- modelling EMILIA VYNNYCKY and RICHARD G WHITE.
- https://anintroductiontoinfectiousdiseasemodelling.com/.

Data availability / Code availability:

- Code will be deposited in the Open Research Data Repository of the Max Planck Society,
- Edmond [\(https://edmond.mpg.de\)](https://edmond.mpg.de/), before publishing.
-

Acknowledgements:

- This work was supported by the Max Planck Society (Berlin, Germany). Computations were
- performed at the Max Planck Computing and Data Facility (MPCDF). We thank Professor
- Pejman Rohani for his valuable feedback on the manuscript.
-

Author contributions:

- EG and MDdC conceptualized the project, and designed the methods. Implementation was
- carried out by EG, and reviewed by LABG. EG and MDdC wrote the manuscript, with support

from MB and LABG. MDdC supervised the project.

Figures:

 Figure 1: Trade-off in risks and resulting framework for calculating the optimal age to recommend MCV1. a) Illustration of the risk trade-off that should be balanced when recommending MCV1 age. b) Conceptual framework for calculating the optimal age to recommend MCV1. Gray boxes indicate variables used to parameterize the mechanistic model of measles transmission and vaccination. Values in brackets indicate the number of variants used. The yellow dots and box reflect incidence, the blue arrow and line the minimization of the incidence, and red indicates the age at minimum incidence, the optimal age.

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.11.20.23298759;](https://doi.org/10.1101/2023.11.20.23298759) this version posted November 20, 2023. The copyright holder for this
preprint **(which was not certified by peer review) is th**e author/funder, who has gran

It is made available under a CC-BY 4.0 International license.

622 **Figure 2: Map and distribution of recommended MCV1 ages.** Reported recommended 623 MCV1 ages by country, from the WHO¹⁶, ECDC¹⁷, and country-based reporting¹⁸⁻²³. The 624 histogram indicates the number of countries recommending MCV1 vaccination at each age. 625

It is made available under a CC-BY 4.0 International license.

 Figure 3: The impact of recommended MCV1 age on the effective vaccine coverage. a) MCV1 effectiveness with age of receipt. VE estimates are indicated with points, with vertical lines indicating the 95% confidence interval and horizontal lines indicating uncertainty in MCV1 age. The SCAM model is indicated in gray; the shaded area indicates the approximate simultaneous 95% confidence interval, and the lines indicate the 2.5%, 25%, MLE, 75%, and 97.5% quantiles. b) Cumulative delay distributions. Cluster medoids are bolded, with points showing the associated delay data. c) Cumulate effective MCV1 coverage when recommending MCV1 at 6, 9, and 12 months, with long delay distribution. Cumulative vaccine coverage after 24 months is set to 100%. Dashed lines indicate the MCV1 coverage, points indicate the effective MCV1 coverage, with vertical lines indicating the 95% confidence intervals. d) Cumulative effective MCV1 coverage at 18 months when recommending MCV1 at 6, 9, and

- 638 12 months, for long and short delay distributions. Points indicate MLE estimates, and vertical
- 639 lines indicate the 95% confidence intervals.

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.11.20.23298759;](https://doi.org/10.1101/2023.11.20.23298759) this version posted November 20, 2023. The copyright holder for this
preprint **(which was not certified by peer review) is th**e author/funder, who has gran

It is made available under a CC-BY 4.0 International license.

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.11.20.23298759;](https://doi.org/10.1101/2023.11.20.23298759) this version posted November 20, 2023. The copyright holder for this
preprint **(which was not certified by peer review) is th**e author/funder, who has gran

It is made available under a CC-BY 4.0 International license.

 Figure 5: Estimating the optimal age to recommend measles vaccination. a) Estimated annual incidence when recommending MCV1 at ages 6–20 months, with 45% MCV1 coverage. Each line indicates the relative incidence for a given parameter set, relative to the minimum incidence for that parameter set. b) Heatmap of optimal ages. Opacity indicates the proportion of parameter sets with an optimum in a given MCV1 age. For clarity, the results for 55% and 75% vaccination coverage are not displayed.

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.11.20.23298759;](https://doi.org/10.1101/2023.11.20.23298759) this version posted November 20, 2023. The copyright holder for this
preprint **(which was not certified by peer review) is th**e author/funder, who has gran

It is made available under a CC-BY 4.0 International license.

656 **Tables:**

SCM	Optimal age	Incidence at the	% Increased incidence		
		optimal age	9 months	12 months	
China	10(9, 12)	747 (729, 766)	0(0, 1)	0(0, 1)	High
India	7(6, 8)	823 (796, 856)	1(0, 2)	4(3, 7)	transmission,
Japan	9(7, 10)	784 (752, 824)	0(0, 1)	2(1, 4)	45% MCV1 coverage
Moscow	9(7, 10)	782 (754, 815)	0(0, 1)	2(1, 4)	
South Africa	6(6, 7)	846 (820, 876)	2(1, 3)	6(4, 8)	
UK	7(6, 8)	814 (782, 852)	1(0, 2)	5(3, 8)	
USA	8(7, 9)	796 (766, 832)	0(0, 1)	3(1, 5)	
China	17(15, 20)	169 (124, 196)	15(8, 30)	4(2, 11)	Low
India	13(11, 15)	205 (159, 237)	7(2, 14)	1(0, 2)	transmission, 85% MCV1 coverage
Japan	16(14, 19)	173 (126, 203)	14(7, 28)	4(1, 10)	
Moscow	16(13, 19)	174 (125, 208)	13(6, 27)	3(0, 11)	
South Africa	13(11, 15)	206 (151, 244)	6(1, 16)	1(0, 3)	
UK	13(12, 16)	190 (141, 223)	9(3, 19)	1(0, 4)	
USA	16(13, 18)	181 (133, 212)	12(6, 25)	3(0, 8)	

657 **Table 1: Estimated optimal ages and annual incidences.** Optimal age indicates the mean 658 (95% confidence interval) of the optimal ages from all parameter sets for the scenario. 659 Incidence indicates the mean (95% confidence interval) annual incidence per 100,000 of the

- 660 parameter sets at the optimal ages. Percentage increased incidence reflects the mean of the
- 661 incidence increase compared to the optimal age incidence.